INSM — Insmed Income Statement
0.000.00%
Last trade - 00:00
- $3.61bn
- $4.02bn
- $305.21m
- 37
- 10
- 75
- 35
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 136 | 164 | 188 | 245 | 305 |
Cost of Revenue | |||||
Gross Profit | 112 | 125 | 144 | 190 | 240 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 372 | 430 | 581 | 703 | 1,015 |
Operating Profit | -235 | -265 | -393 | -457 | -710 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -254 | -293 | -436 | -480 | -747 |
Provision for Income Taxes | |||||
Net Income After Taxes | -254 | -294 | -435 | -482 | -750 |
Net Income Before Extraordinary Items | |||||
Net Income | -254 | -294 | -435 | -482 | -750 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -254 | -294 | -435 | -482 | -750 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.01 | -3.01 | -3.73 | -4.02 | -5.2 |